Aprea Therapeutics is accelerating enrollment in its Phase 1 dose-escalation study of APR-1051, a WEE1 kinase inhibitor in DNA damage response, after early signs of clinical activity. The company plans to broaden the trial’s patient populations and add combination arms, increasing active clinical sites from three to 10 and targeting higher monthly enrollment. Aprea also outlined additional expansion into uterine serous carcinoma and Cyclin E–overexpressing platinum-resistant ovarian cancer, plus arms for HPV-positive head and neck squamous cell carcinoma and colorectal cancer in combination with standard-of-care therapies, aiming to complete expansions in 2027.